A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

Stopped early

Conditions studied: Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies

In brief

This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease. Part 2 comprises an observational period of 5 visits over a period up to 8 weeks. During Part 2, baseline tests will be conducted, and urine will be collected approximately every 2 weeks for 8 weeks. Patients may participate in Part 1, Part 2, or both, and will be followed for up to 1 year consisting of data collection from the patient's medical records and home collection of urine samples every 4 months.

Key facts

Study ID: NCT04235621
Run by: Goldfinch Bio, Inc.
People needed: 20
Starts: 2019-12-20
Expected to finish: 2020-05-27
Last updated by the study team: 2021-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

For FSGS/TR-MCD patients :
Competent and willing to provide informed consent and adhere to all study assessments and restrictions.
Male or female ≥ 18 years of age with FSGS or TR-MCD at the time of providing written informed consent.
Diagnosis of FSGS or TR-MCD, based on either biopsy or genetic testing.
Urinary protein to creatinine ratio (UPCR) ≥ 1.0 g/g.
Estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2.
For DN patients:
Competent and willing to provide informed consent and adhere to all study assessments and restrictions.
Male or female ≥ 18 years of age with DN at the time of providing written informed consent.
Diagnosis of type 2 diabetes
Urinary albumin to creatinine ratio (UACR) ≥ 150 mg/g.
Estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2.

You may not qualify if…

For FSGS/TR-MCD patients:
Evidence of another kidney disease or kidney disease secondary to an infectious process.
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. Patients whose results are compatible with prior immunization or treatment may be included.
Body mass index (BMI) > 42 kg/m2.
Significant history or evidence of clinically significant disorder, condition, current illness, or disease that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion (eg, severe cardiac disease, cardiac conduction defect, or severe or chronic hepatobiliary disease).
History of malignancy not in remission within the last 5 years other than adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.
History of any organ or bone marrow transplant, including kidney grafts.
History of alcoholism or drug/chemical abuse within 12 months.
Preplanned surgery or procedures that would interfere with the conduct of the study.
For DN patients:
Evidence of another kidney disease or kidney disease secondary to an infectious process.
History of HIV, hepatitis B, or hepatitis C. Patients whose results are compatible with prior immunization or treatment may be included.
BMI > 42 kg/m2.
Significant history or evidence of clinically significant disorder, condition, current illness, or disease that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion (eg, severe cardiac disease, cardiac conduction defect, or severe or chronic hepatobiliary disease).
History of malignancy not in remission within the last 5 years other than adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.
History of any organ or bone marrow transplant, including kidney grafts.
History of alcoholism or drug/chemical abuse within 12 months.
Preplanned surgery or procedures that would interfere with the conduct of the study.
Renal disease that requires immunosuppressive therapy (currently, or in the past).

Where it is running

Aventiv Research - Phoenix — Mesa, Arizona, United States
Glendale Adventist Medical Center — Glendale, California, United States
DaVita Mojave Sage Dialysis — Victorville, California, United States
Colorado Kidney Care — Denver, Colorado, United States
Renal and Transplant Associates of New England, PC — Springfield, Massachusetts, United States
St. Clair Nephrology — Roseville, Michigan, United States
DaVita Clinical Research — Minneapolis, Minnesota, United States
Clinical Research Consultants — Kansas City, Missouri, United States
DaVita Pelican Point Dialysis — Las Vegas, Nevada, United States
High Desert Nephrology — Gallup, New Mexico, United States
Akron Nephrology Associates, Inc. — Akron, Ohio, United States
Southeast Renal Research Institute — Chattanooga, Tennessee, United States
Arlington Nephrology, PC — Arlington, Texas, United States
North Texas Kidney Disease Association — Lewisville, Texas, United States
South Texas Renal Care Group (Downtown) — San Antonio, Texas, United States
San Antonio Kidney Disease Center Physicians Group (Wurzbach Road) — San Antonio, Texas, United States
South Texas Renal Care Group (Westover Hills) — San Antonio, Texas, United States
San Antonio Kidney Disease Center Physicians Group (Carnoustie Drive) — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.